Finished
Robotic Versus Open Surgery Following Neoadjuvant Therapy in Pancreatic Cancer: Evaluation of Safety and Oncologic Outcomes
NCT07147374 · Peking Union Medical College Hospital · Updated 29 Aug 2025
- What is being tested
- Not stated
- For
- Pancreatic Cancer; Neoadjuvant Therapy; Robotic Surgery
- Kind of study
- Watches patients without assigning a treatment. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 56 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 1 Feb 2017, ends 31 July 2025. Registered 29 Aug 2025.
- Results
- None posted yet.
In the researchers' words
The feasibility and safety of minimally invasive surgery in cases after neoadjuvant therapy were unclear. It is worth exploring the safety of robotic resection for pancreatic cancer following neoadjuvant therapy. The investigators investigated the comparative outcomes of robotic and open surgery in the management of pancreatic cancer after NAT, exploring the feasibility and safety of robotic procedures in complex cases of pancreatic cancer, and providing evidence-based guidance for clinical practice.
Sites
- Department of General Surgery, Peking Union Medical College Hospital (PUMCH)Beijing, Beijing Municipality, China